Drug evaluation: Vilazodone - A combined SSRI and 5-HT1A partial agonist for the treatment of depression

IDrugs

Volumn 10, Issue 3, 2007, Pages 193-201

  De Paulis, Tomas ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; DIAZEPAM; EMD 86006; EMD 95750; EPTAPIRONE; FLESINOXAN; GEPIRONE; IPSAPIRONE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [3 [4 [4 (CYCLOHEXYLMETHYLSULFONAMIDO)BUTYL] 1 PIPERAZINYL]PHENYL]ACETAMIDE; OPC 14523; PAROXETINE; PINDOLOL; PIPERAZINE DERIVATIVE; ROXINDOLE; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VILAZODONE; VN 2222;

ARTICLE; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SYNTHESIS; ELECTRIC SHOCK; FOOTSHOCK; FORCED SWIMMING TEST; GENETIC MARKER; HUMAN; MAJOR DEPRESSION; MENTAL CONCENTRATION; NAUSEA; NONHUMAN; PARASOMNIA; REM SLEEP; SIDE EFFECT; STOMACH PAIN; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BENZOFURANS; CLINICAL TRIALS; DEPRESSION; DRUG EVALUATION, PRECLINICAL; HUMANS; INDOLES; MOLECULAR STRUCTURE; PATENTS; PIPERAZINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN UPTAKE INHIBITORS;

EID: 33947326248     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. 1A/B agonist, eltoprazine, on behavioral satiety sequence. McGuirk J, Muscat R, Willner P PHARMACOL BIOCHEM BEHAV 1992 41 4 801-805
2. 92532 A role for the serotonin system in the mechanism of action of antidepressant treatments: Preclinical evidence. Blier P, de Montigny C, Chaput Y J CLIN PSYCHIAT 1990 51 4 14-21
3. 191261 Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD-49980 (roxindole). Results of an open clinical study. Klimke A, Klieser E PHARMACOPSYCHIAT 1991 24 4 107-112
4. 2 autoreceptor agonist. Bartoszyk GD, Harting J, Minck K-O J PHARMACOL EXP THER 1996 276 1 41-48
5. 243757 Pindolol induces a rapid improvement in patients with depression treated with serotonin uptake inhibitors. Artigas F, Perez V, Alverez E ARCH GEN PSYCHIAT 1994 51 3 248-251
6. 243759 Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. Blier P, Bergeron R J CLIN PSYCHOPHARMACOL 1995 15 3 217-222
7. 1A agonist activity in an animal behavioral model.
8. 290882 The serotonin hypothesis of major depression. Maes M, Meltzer HY PSYCHOPHARMACOLOGY: THE FOURTH GENERATION OF PROGRESS Bloom FE, Kupfer DJ (Eds). Raven Press, New York, NY, USA 933-944
9. 290997 Effect of pindolol on hormone secretion and body temperature: Partial agonist effects. Meltzer HY, Maes M J NEURAL TRANS 1996 103 1-2 77-88
10. 1A antagonistic properties combined in a single NCE. Bottcher H, Andersson B, Bartoszyk GD, Devant R, Greiner HE, Hansson L, Seyfried CA, Sonesson C, Sternlof P ABSTR SOC NEUROSCI 1998 24 Pt 1 Abs 438.5
11. 305090 Highlights from the 28th Annual Meeting of the Society for Neuroscience (Part II) Los Angeles, California. Gray D, Nicholls R IDDB MEETING REPORT 1998 November 7-12
12. 1A receptors. Tordera R, Monge A, Del Rio J, Lasheras B METHOD FIND EXP CLIN PHARMACOL 1999 21 Suppl A 197
13. 356600 Three- and four-dimensional-quantitative structure-activity relationship (3-D/4-D-QSAR) analyses of CYP2D6 inhibitors. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA PHARMACOGENETICS 1999 9 4 477-489
14. 399224 GlaxoSmithKline and Merck KGaA sign worldwide agreement on antidepressant. GlaxoSmithKline plc PRESS RELEASE 2001 February 15
15. 1A serotonin receptors and serotonin transporter, as a new class of antidepressants. Martinez-Esparza J, Oficialdegui AM, Pere-Silanesz S, Heras B, Orus L, Palop J-A, Lasheras B, Roca J, Mourelle M, Bosch A, Del Castillo JC et al J MED CHEM 2001 44 3 418-428
16. 1A receptor activation and antidepressant-like effects: F-13714 has high efficacy and marked antidepressant potential. Koek W, Vacher B, Cosi, Assie M-B, Patoiesau J-F, Pauwels PJ, Colpaert FC EUR J PHARMACOL 2001 420 2-3 103-112
17. 1A receptor agonist OPC-14523. Tottori K, Miwa T, Uwahodo Y, Yamada S, Nakai M, Oshiro Y, Kikuchi T, Altar CA NEUROPHARMACOL 2001 41 8 976-988
18. 486369 Merck KGaA and GlaxoSmithKline agree to end joint vilazodone development. Merck KGaA PRESS RELEASE 2003 April 17
19. 492104 Merck KGaA presentation 1st Quarter 2003. Merck KGaA 1ST QUARTER REPORT 2003 April 29
20. 1A receptor agonist. Romero L, Celada P, Martin-Ruiz R, Diaz-Mataix L, Mourelle M, Delgadillo J, Hervas I, Artigas F NEUROPSYCHOPHARMACOL 2003 28 3 445-456
21. 1A receptors. Tordera RM, Monge A, Del Rio J, Lasheras B EUR J PHARMACOL 2002 442 1-2 63-71
22. 542128 3,4-Dihydro-2(1H)-quinolinone as a novel antidepressant drug: Synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1- piperazinyl]-propyl]-3,4-dihydro-5-methoxy-2(1H) -quinolinone. Oshiro Y, Sakurai Y, Sato S, Kurahashi N, Tanaka T, Kikuchi T, Tottori K, Uwahodo Y, Miwa T, Nishi T J MED CHEM 2000 43 2 177-189
23. 560430 Genaissance Pharmaceuticals Licenses Compound from Merck KGaA. Genaissance Pharmaceuticals Inc PRESS RELEASE 2004 September 23
24. 575913 A new synthesis of indole 5-carboxylic acids and 6-hydroxyindole-5-carboxylic acids in the preparation of an o-hydroxylated metabolite of vilazodone. Heinrich T, Bottcher H BIOORG MED CHEM LETT 2004 14 10 2681-2684 • Synthesis of the active metabolite of vilazodone.
25. 627525 Clinical Data acquires Genaissance for $56 million. Clinical Data Inc PRESS RELEASE 2005 October 07
26. 647220 Clinical Data starts pivotal trial of antidepressant. Clinical Data Inc PRESS RELEASE 2006 January 26
27. 658933 Clinical Data initiates patient enrollment for vilazodone phase 3 clinical trial; top-line data anticipated in mid-2007. Clinical Data Inc PRESS RELEASE 2006 March 30
28. 660378 Pharmos sets strategic priorities for development of Vela compounds. Pharmos Corp PRESS RELEASE 2006 April 05
29. 667315 Clinical Data to spin-out company for antidepressant drug. Clinical Data Inc PRESS RELEASE 2006 May 15
30. 676859 Depression & Anxiety - SMi's Second Conference, London, UK. Kneller S IDDB MEETING REPORT 2006 June 28-29
31. 1A agonist (PRX-00023) for the treatment of anxiety and depression. Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, Heifetz A, Mohanty P, Fichman M, Sharadendu A, Nudelman RS J MED CHEM 2006 49 11 3116-3135
32. 684982 Clinical Data's vilazodone patient enrollment over one-third complete. Clinical Data Inc PRESS RELEASE 2006 August 17
33. 1A receptor agonist in a functional test in the rodent brain.
34. 1A receptor antagonist.
35. 1A agonists and 5-HT reuptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity. Heinrich T, Bottcher H, Schiemann K, Holzemann G, Schwarz M, Bartoszyk GD, van Amsterdam C, Greiner HE, Seyfried CA BIOORG MED CHEM 2004 12 18 4843-4852
36. 688274 Phase I and II enzyme characterization of two sources of HepG2 cell lines. Hewitt NJ, Hewitt P XENOBIOTICA 2004 34 3 243-256
37. 688275 Effects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats. Adamec R, Bartoszyk GD, Burton P EUR J PHARMACOL 2004 504 1-2 65-77
38. 688276 Behavioral and neurochemical effects of 5-(4-[4-(5-cyano-3- indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD-68843): A combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. Page ME, Cryan JF, Sullivan Arthur DA, Saucy B, Manning DR, Lucki I J PHARMACOL EXP THER 2002 302 3 1220-1227 • Vilazodone raises serotonin levels in rat frontal cortex to 3-fold those of fluoxetine.
39. 688277 Studies comparing in vivo:in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey and human using cryopreserved hepatocytes, microsomes and collagen gel-immobilized hepatocyte cultures. Hewitt NJ, Buhring KU, Dasenbrock J, Haunschild J, Ladstetter B, Utesch D DRUG METAB DISPOS 2001 29 7 1042-1050
40. 688279 Systemic EMD-68843 injections reduce anxiety in the shockprobe, but not the plus-maze test. Treit D, Degroot A, Kashluba S, Bartoszyk GD EUR J PHARMACOL 2001 414 2-3 245-248
41. 1A agonists, vilazodone increases slow-wave sleep in this phase 1 clinical trial.
42. 1A receptor occupancy in human brain.
43. 688285 Fast adaptive changes of the sleep regulatory system after a single dose of the putative antidepressive substance EMD-68843. Murck H, Frieboes RM, Antonijevic IA, Steiger A PHARMACOPSYCHIATRY 1999 32 Abs 146
44. 692736 Mixed results for EPIX's PRX-00023 in phase III anxiety trial. EPIX Pharmaceuticals Inc PRESS RELEASE 2006 September 22
45. 1A agonist F-13714: A microdialysis study in the rat. Assie M-B, Lomenech H, Ravailhe V, Faucillon V, Newman-Tancredi A BR J PHARMACOL 2006 149 2 170-178
46. 736653 Safety and efficacy study of vilazodone and discovering genetic markers associated with response in patients with major depressive disorder. www.clinicaltrials.gov WEB SITE 2006 October 30
47. 741195 The future of selective serotonin reuptake inhibitors (SSRIs) in psychiatric treatment. Taylor S, Stein MB MED HYPOTHESES 2006 66 1 14-21
48. 741551 Brain serotonin neurotransmission. Murphy DL, Andrews AM, Wichems CH, Tohda M, Greenberg B J CLIN PSYCHIAT 1998 59 15 4-12
49. 741680 The augmention hypothesis for improvement of antidepressant therapy. Kinney GG, Taber MT, Gribkoff VK MOL NEUROBIOL 2000 21 3 137-152
50. 741686 Pindolol augmentation of antidepressant response. Artigas F, Adell A, Celada P CURR DRUG TARGETS 2006 7 2 139-147
51. 741691 Pharmacology of rapid-onset antidepressant treatment strategies. Blier P J CLIN PSYCHIAT 2001 62 Suppl 15 12-17
52. 1A receptor agonists and serotonin reuptake inhibitors. Heinrich T, Bottcher H, Gericke R, Bartoszyk GD, Anzali S, Seyfried CA, Greiner HE, van Amsterdam C J MED CHEM 2004 47 19 4684-4692 • Optimization of the benzofuran moiety and preclinical characterization of vilazodone.
53. 742255 Mechanism of action of antidepressants. Artigas F, Nutt DJ, Shelton R PSYCHOPHARMACOL BULL 2002 36 2 123-132
54. 11C]WAY-100635. Effects of depression and antidepression treatment. Sargent PA, Husted-Kjaer K, Bench CJ, Rabiner EA, Messa C, Meyer J, Gunn RN, Grasby PM, Cowen PJ ARCH GEN PSYCHIAT 2000 57 2 174-180
55. 742264 Behavioral depression and positron emission tomographydetermined serotonin 1A receptor binding potential in cynomolgus monkeys. Shively CA, Friedman DP, Gage HD, Bounds MC, Brown-Proctor C, Blair JP, Henderson JA, Smith MA, Buchheimer N ARCH GEN PSYCHIAT 2006 63 4 396-403
56. 1A receptors. Lejeune F, Millan MJ EUR J NEUROSCI 2000 12 9 3265-3275
57. 742323 Effects of chronic fluoxetine treatment in the presence and absence of (+/-)pindolol: A microdialysis study. Dawson LA, Nguyen HQ, Smith DL, Schlechter LE BR J PHARMACOL 2000 130 4 797-804
58. 742337 Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex. Dawson LA, Nguyen HQ, Smith DL, Schlechter LE J PSYCHOPHARMACOL 2002 16 2 145-152
59. 1A receptor ligands to pre- and postsynaptic receptors by (-)pindolol. A comparative study in rodent, primate and human brain. Raurich A, Mengod G, Artigas F, Cortes R SYNAPSE 1999 34 1 68-76
60. 1A serotonin receptors and serotonin transporter as a new class of antidepressants. Martinez J, Perez S, Oficialdegui AM, Heras B, Orus L, Villanueva H, Palop JA, Roca J, Mourelle M, Bosch A, Del Castillo J-C et al EUR J MED CHEM 2001 36 1 55-61
61. 1A receptors. Jordan S, Chen R, Koprivica V, Hamilton R, Whitehead RE, Tottori K, Kikuchi T EUR J PHARMACOL 2005 517 3 165-173
62. 742633 Strategies for producing faster-acting antidepressants. Adell A, Castro E, Celada P, Bortolozzi A, Pazos A, Artigas F DRUG DISCOV TODAY 2005 10 8 578-585
63. 743137 Chronic treatment with eltoprazine does not lead to tolerance in its anti-aggressive action, in contrast to haloperidol. Mos J, van Aken HH, van Oorschot R, Oliver B LIFE SCI 1997 61 1 11-19
64. 1A agonists. Heinrich T, Bottcher H, Bartoszyk GD, Greiner HE, Seyfried CA, Van Amsterdam C J MED CHEM 2004 47 19 4677-4683
65. 753553 Clinical data completes vilazodone manufacturing technology transfer under license with Merck KGaA. Clinical Data Inc PRESS RELEASE 2006 December 22
66. 1A/1B antagonistic activity: A new approach toward efficient antidepressants. Matzen L, van Amsterdam C, Rautenberg W, Greiner HE, Harting J, Seyfried CA, Bottcher H J MED CHEM 2000 43 6 1149-1157
67. 763333 Two-week delay in onset of action of antidepressants: New evidence. Mitchell AJ BR J PSYCHIATRY 2006 188 2 105-106
68. 763345 Early onset of selective serotonin reuptake inhibitor antidepressant action: Systematic review and meta-analysis. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z ARCH GEN PSYCHIATRY 2006 63 11 1217-1223